Paradigm4, inc.
Paradigm4 provides the REVEAL Integrative Analytics Platform, a scientific DBMS and analytics solution built on SciDB, serving global pharmaceutical and biotechnology companies with multimodal data integration, AI-driven target discovery, and high-performance computing for life sciences research.
- Company typePrivate
- Founded2015
- HeadquartersWaltham, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Paradigm4, inc. does
Paradigm4, Inc. is a privately held, tech-enabled data science company that builds and sells the REVEAL Integrative Analytics Platform to global pharmaceutical and biotechnology customers for target discovery, AI result validation, and large-scale life sciences analytics. The company serves named enterprise customers including Alnylam, Amgen, Janssen, Bristol Myers Squibb, Maze Therapeutics, Agios, SiteTx, and 54gene, addressing pain points around integrating multimodal genotypic, phenotypic, imaging, and clinical data, and accelerating computation on population-scale biobank datasets.
The core technology stack is the SciDB computational database engine, originally incubated at MIT by Turing Award laureate Michael Stonebraker, combined with an elastic computing engine and the flexFS hyperscale file system. REVEAL is sold as a platform-plus-modules product, with specialized applications for Biobank exploration, Multi-Omics, SingleCell analysis (with a Precision Cell Atlas feature), and Analytical Development. flexFS, positioned as a standalone core product, claims 100–1,000x faster computations and 50% lower storage cost than Lustre or EFS benchmarks. The company is ISO 27001:2022 certified and offers a Trusted Research Environment for regulated workloads.
Paradigm4 generates revenue through enterprise subscriptions to REVEAL (and its modular applications) plus Tech Enabled Services for implementation and data science consulting. Pricing is quote-based and varies by application mix, data scale, and cloud footprint, on annual billing cycles. Go-to-market is direct enterprise field sales with a consultative, sales-led motion; flagship customers like Alnylam are positioned as foundational, multi-year, pipeline-level engagements. The company has disclosed only two early funding rounds (2011 and 2015, both with undisclosed amounts) and shows no recent venture funding, M&A, or IPO activity, suggesting a leanly funded, founder-led operating profile.
Paradigm4, inc. firmographics
Firmographics- Name
- Paradigm4, inc.
- Legal name
- Paradigm4, Inc.
- Website
- https://paradigm4.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Paradigm4 provides the REVEAL Integrative Analytics Platform, a scientific DBMS and analytics solution built on SciDB, serving global pharmaceutical and biotechnology companies with multimodal data integration, AI-driven target discovery, and high-performance computing for life sciences research.
- Ownership category
- akta.pro rank
Paradigm4, inc. industry classification
Industry- Product category
- Scientific Database & Life Sciences Analytics Platform
- NAICS
- Software Publishers (5132), Scientific Research and Development Services (5417)
- SIC
- Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
- akta.pro secondary industries
- Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF)
Keywords
Where Paradigm4, inc. is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Paradigm4, inc. business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- REVEAL Platform Subscription: Paradigm4 generates revenue through platform subscriptions for their REVEAL Integrative Analytics Platform. The platform is offered as a cloud-based scientific analytics solution with pricing based on usage, scale, and specific applications (Biobank, SingleCell, Multi-Omics, Digital, Imaging). The company also offers Tech Enabled Services to support implementation and optimization.
- Tech Enabled Services: Professional services including implementation, data science consulting, and technical support to complement the platform offering. These services help customers maximize value from the REVEAL platform and address specific technical requirements.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise platform access with modular applications |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Paradigm4, inc. product offering
Product offeringCore offering
Paradigm4 builds and sells SciDB, a scalable scientific database management system, and the REVEAL Integrative Analytics Platform, which integrates a novel scientific data store with an elastic computing engine to manage, explore, and analyze highly dimensional, multimodal life sciences data (genotypic, phenotypic, imaging, health records). The company also sells flexFS, a hyperscale file system for AI/ML and large-file workloads, and offers Tech Enabled Services and a Trusted Research Environment to support enterprise life sciences customers.
Product overview
Paradigm4 is a tech-enabled data science company offering the REVEAL Integrative Analytics Platform as its core unified product. REVEAL is a multimodal evidence platform that combines a novel scientific data store with an elastic computing engine, enabling no-code to low-code exploration, comprehensive analytics, and machine learning. The platform operates as a platform-plus-modules architecture, with specialized applications including REVEAL Biobank (for biobank data exploration), REVEAL Multi-Omics (for cross-study omics analyses), REVEAL SingleCell with Precision Cell Atlas (for single-cell analysis), and REVEAL Analytical Development (for pharmaceutical data management). The technology stack is built on SciDB computational database engine. flexFS serves as the high-performance file system foundation, delivering over 500x higher throughput than leading elastic solutions at under half the cost. The company also provides Tech Enabled Services and Trusted Research Environments as supporting service offerings.
Differentiator
Problem solved
Functional benefit
Brands
- REVEAL: Integrative Analytics Platform for life sciences and drug discovery, including Multi-Omics, SingleCell, and Biobank applications
- flexFS
- REVEAL: Multi-Omics App
- REVEAL: SingleCell App
- REVEAL: Biobank App
- REVEAL: Analytical Development App
Products and services
- REVEAL Integrative Analytics Platform A multimodal evidence platform that integrates a novel scientific data store with an elastic computing engine for no-code to low-code exploration, comprehensive analytics, and machine learning on high-dimensional life sciences data. Sold to global pharmaceutical and biotechnology firms for target discovery, AI validation, and evidence generation for portfolio prioritization.
- flexFS A hyperscale file system designed for AI/ML and large file data workloads, providing object storage economics with full filesystem performance. Delivers 50% lower cost than comparable solutions and over 500x higher throughput than leading elastic alternatives; targets genomics, HPC, and AI workloads in life sciences.
- REVEAL Biobank An application for exploring and querying biobank data with cohort selector tools, providing easy access to high-resolution, multi-dimensional and multi-attribute data. Enables fluid combination of genotypic, phenotypic, biomedical imaging, and health records with an R API for scalable analytics and machine learning.
- REVEAL Multi-Omics A multi-omics application that enables researchers to run advanced cross-study analyses with quick searches for genes and proteins across integrated public reference and proprietary datasets.
- REVEAL SingleCell A single-cell analysis application including the Precision Cell Atlas feature, enabling scientists to selectively combine unlimited samples from multiple datasets to create custom cell atlases for specific research objectives and explicit reuse.
- REVEAL Analytical Development An analytical development data management tool that enables data analysts to unlock Allotrope Data Format (ADF) data and identify critical quality attributes in pharmaceutical development workflows.
- Tech Enabled Services Technology-enabled data science services that work alongside global life science firms to accelerate disease understanding and drug discovery, combining bioinformatics, computer science, biology, and cloud expertise. Includes implementation, data science consulting, and technical support for REVEAL deployments.
- Trusted Research Environment A secure, compliant research environment for life sciences organizations to conduct sensitive research with appropriate data governance and security controls. Supports collaborative work while maintaining data security and regulatory compliance, backed by ISO 27001:2022 certification.
Quantifiable outcome
- 100-1000x faster computations enabling rapid target discovery
- +3 more outcomes
Companies that use Paradigm4, inc.
Customer profileNamed customers9 records
Segments3 records
Ideal customer profiles3 records
Paradigm4, inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature6 records
Paradigm4, inc. partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship and core.
- Alnylam PharmaceuticalsflagshipFoundational partnership where Paradigm4's REVEAL Integrative Analytics platform enables Alnylam to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets. The partnership underlies Alnylam's RNAi therapeutics pipeline productivity and has enabled discovery of therapeutic targets including INHBE. Alnylam can go from target discovery to Phase 1 clinical trial in as little as 18 months using Paradigm4's platform.
- TetraSciencecoreParadigm4 joined the Tetra Partner Network (TPN) to leverage Tetra Data as a foundation for analytical computing applications. This integration allows pharmaceutical customers to accelerate research decision-making using Tetra Data combined with Paradigm4's high-performing analytical computing capabilities.
- 54genecoreAgreement allowing 54gene to use Paradigm4's REVEAL Biobank app to explore, characterize and query data within 54gene's African Health Information Ecosystem. The ecosystem contains highly curated clinical, phenotypic and genetic information from African populations for drug discovery and therapeutic insights.
- UK BiobankcoreParadigm4's platform integrates data from UK Biobank, one of the world's most comprehensive health databases. This integration enables customers to perform population-scale biobank genotype-phenotype analyses for drug target discovery.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Paradigm4, inc. competitors and assessment
Company assessmentDirect peers
- DNAnexus: Cloud-based genomics and biomedical data analysis platform serving pharma, biotech, and clinical labs. Directly comparable to Paradigm4 in life sciences data management, multimodal integration, and enterprise pharma GTM.
- Lifebit Biotech: Genomics and biomedical data platform offering federated, cloud-native analysis for population-scale biobanks. Closely comparable in target market (pharma + national genomics initiatives) and multimodal data integration focus.
- BC Platforms: Genomic and clinical data management platform with strong biobank and pharma R&D focus. Comparable in serving pharma target discovery from population-scale genotype-phenotype data.
- Velsera (formerly Seven Bridges): Life science analytics and bioinformatics platform serving pharma, biotech, and clinical customers. Directly competes in multimodal life sciences data analysis and target discovery workflows.
Emerging players
- Form Bio: Life sciences data analytics and bioinformatics platform from a recent spin-out. Overlaps with Paradigm4 in multi-omics, single-cell, and pharma R&D data workflows but with a newer, cloud-native stack.
Broad incumbents
- Databricks: Unified data and AI platform with significant life sciences and genomics offerings (e.g., Databricks Genomics, BioNeMo). Competes more broadly in multimodal data analytics, with the resources and cloud partnerships that Paradigm4 lacks.
- Palantir Technologies: Data integration and analytics platform with Foundry in pharma R&D and population health use cases. Broad incumbent in multimodal data integration and evidence generation for life sciences.
- Dotmatics: Life sciences R&D informatics platform spanning discovery, biology, and analytical workflows. A broad incumbent in pharma R&D data management and analytics, with overlapping enterprise customer base.
- Revvity Signals (formerly Core Informatics): Lab and scientific data management software (LIMS/ELN) within Revvity's life sciences portfolio. Adjacent as an established informatics provider in pharma/biotech R&D, though more focused on laboratory data capture.
Others
- TetraScience: Cloud-native R&D data platform for life sciences, already a strategic partner of Paradigm4 via the Tetra Partner Network. Comparable as a data infrastructure layer feeding analytics platforms, with overlapping pharma customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Paradigm4, inc. social profiles
Digital presenceParadigm4, inc. compliance and trust
Trust signalCompliance1 record
Paradigm4, inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Paradigm4, inc. leadership team
Management profileNumber of profiles
Profiles9 records
Paradigm4, inc. funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Paradigm4, inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Paradigm4, inc.
What does Paradigm4, inc. do?
Paradigm4 builds and sells SciDB, a scalable scientific database management system, and the REVEAL Integrative Analytics Platform, which integrates a novel scientific data store with an elastic computing engine to manage, explore, and analyze highly dimensional, multimodal life sciences data (genotypic, phenotypic, imaging, health records). The company also sells flexFS, a hyperscale file system for AI/ML and large-file workloads, and offers Tech Enabled Services and a Trusted Research Environment to support enterprise life sciences customers.
Is Paradigm4, inc. a public or private company?
Paradigm4, inc. is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Paradigm4, inc. founded?
Paradigm4, inc. was founded in 2015. It employs 11 to 50 people.
Where is Paradigm4, inc. based?
Paradigm4, inc. is headquartered in Waltham, United States, in the North America region.
How does Paradigm4, inc. make money?
Two revenue lines are on record. REVEAL Platform Subscription is the primary driver. The others are tech Enabled Services.
Who are Paradigm4, inc.'s main competitors?
Direct peers on record are DNAnexus, Lifebit Biotech, BC Platforms and Velsera (formerly Seven Bridges). Form Bio is listed as an emerging player. Broad incumbents are Databricks, Palantir Technologies, Dotmatics and Revvity Signals (formerly Core Informatics). TetraScience is listed as an others.
Does Paradigm4, inc. have an API?
No public API is recorded for Paradigm4, inc..
What industry is Paradigm4, inc. in?
Paradigm4, inc.'s product category is Scientific Database & Life Sciences Analytics Platform. Its primary akta.pro industry code is HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D), with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 5132 and its SIC code is 7372.